Shares of Hims & Hers (HIMS) have jumped on Friday as the company is preparing to air its first Super Bowl ad promoting its compounded ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...

G/O Media is once again attempting to use AI to churn out content — while simultaneously warning that anything the AI ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...